PT1771468E - Células alojadas em tumores tratadas por engenharia genética para produzir ligandos que induzem apoptose relacionada com a necrose do tumor (liart) - Google Patents

Células alojadas em tumores tratadas por engenharia genética para produzir ligandos que induzem apoptose relacionada com a necrose do tumor (liart) Download PDF

Info

Publication number
PT1771468E
PT1771468E PT05764208T PT05764208T PT1771468E PT 1771468 E PT1771468 E PT 1771468E PT 05764208 T PT05764208 T PT 05764208T PT 05764208 T PT05764208 T PT 05764208T PT 1771468 E PT1771468 E PT 1771468E
Authority
PT
Portugal
Prior art keywords
cells
tumor necrosis
liart
genetic engineering
induce apoptosis
Prior art date
Application number
PT05764208T
Other languages
English (en)
Portuguese (pt)
Inventor
Alessandro M Gianni
Carmelo Carlo-Stella
Francesco Colotta
Original Assignee
Dompe Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe Spa filed Critical Dompe Spa
Publication of PT1771468E publication Critical patent/PT1771468E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4231—Cytokines
    • A61K40/4232—Tumor necrosis factors [TNF] or CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/48—Regulators of apoptosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PT05764208T 2004-07-29 2005-07-21 Células alojadas em tumores tratadas por engenharia genética para produzir ligandos que induzem apoptose relacionada com a necrose do tumor (liart) PT1771468E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04017907A EP1621550A1 (en) 2004-07-29 2004-07-29 Tumor-homing cells engineered to produce tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)

Publications (1)

Publication Number Publication Date
PT1771468E true PT1771468E (pt) 2010-04-20

Family

ID=34925971

Family Applications (1)

Application Number Title Priority Date Filing Date
PT05764208T PT1771468E (pt) 2004-07-29 2005-07-21 Células alojadas em tumores tratadas por engenharia genética para produzir ligandos que induzem apoptose relacionada com a necrose do tumor (liart)

Country Status (24)

Country Link
US (1) US20070264231A1 (enExample)
EP (2) EP1621550A1 (enExample)
JP (1) JP5042826B2 (enExample)
KR (1) KR20070047757A (enExample)
CN (1) CN101076540B (enExample)
AT (1) ATE455847T1 (enExample)
AU (1) AU2005266543B2 (enExample)
BR (1) BRPI0513855A (enExample)
CA (1) CA2571426A1 (enExample)
DE (1) DE602005019050D1 (enExample)
DK (1) DK1771468T3 (enExample)
ES (1) ES2340400T3 (enExample)
HR (1) HRP20100227T1 (enExample)
IL (1) IL180233A (enExample)
MX (1) MX2007001152A (enExample)
NO (1) NO20070956L (enExample)
NZ (1) NZ552223A (enExample)
PL (1) PL1771468T3 (enExample)
PT (1) PT1771468E (enExample)
RS (1) RS51381B (enExample)
RU (1) RU2390558C2 (enExample)
SI (1) SI1771468T1 (enExample)
WO (1) WO2006010558A1 (enExample)
ZA (1) ZA200701231B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0510886A (pt) * 2004-06-18 2007-12-26 Genentech Inc método para aumentar a apoptose ou a citotoxicidade em células de mamìferos
DE102006020307A1 (de) * 2006-05-03 2007-11-08 Martin-Luther-Universität Halle-Wittenberg TNF-related apoptosis-including (TRAIL)stabil transgen exprimierende mesenchymale Stammzellen, Verfahren zu ihrer Herstellung und zu ihrer Verwendung
WO2008142862A1 (ja) * 2007-05-18 2008-11-27 National University Corporation Asahikawa Medical College 血管内皮前駆細胞の移植による抗がん療法
CN102154213B (zh) * 2011-01-19 2012-07-25 郑骏年 一种运载荷载细胞因子的双调控溶瘤腺病毒的新型cik细胞
US20140369979A1 (en) * 2012-02-01 2014-12-18 Postech Academy-Industry Foundation Vector simultaneously expressing dodecameric trail and hsv-tk suicide genes, and anticancer stem cell therapeutic agent using same
CN103288966B (zh) * 2013-05-17 2015-01-21 华侨大学 一种融合受体及其用于治疗大肠癌的基因药物
RU2552609C1 (ru) * 2013-10-28 2015-06-10 Федеральное государственное бюджетное учреждение науки Институт молекулярной биотехнологии им. В.А. Энгельгардта Российской академии наук (ИМБ РАН) Способ получения системы направленной доставки белковых молекул (онколитических белков) в опухолевые ткани на основе активированных лимфоцитов
RU2716821C2 (ru) 2014-10-24 2020-03-17 Калиди Биотерапьютикс, Инк. Комбинированный иммунотерапевтический подход к лечению рака
EP3971284B1 (en) * 2015-07-29 2023-11-08 ONK Therapeutics Limited Modified natural killer cells and natural killer cell lines having increased cytotoxicity
US10906951B2 (en) 2015-07-29 2021-02-02 Onk Therapeutics Limited Modified natural killer cells and natural killer cell lines having increased cytotoxicity
WO2019232631A1 (en) * 2018-06-06 2019-12-12 Stemcell Technologies Canada Inc. Kits, compositions and methods for myeloid-derived suppressor cell enrichment
US12220465B2 (en) 2018-11-28 2025-02-11 Washington University Compositions and methods for targeted treatment and imaging of cancer or tumors
WO2020188105A1 (en) 2019-03-21 2020-09-24 Onk Therapeutics Limited Modified immune effector cells with increased resistance to cell death
EP3712257A1 (en) 2019-03-21 2020-09-23 ONK Therapeutics Limited Modified natural killer cells with increased resistance to cell death
WO2021209625A1 (en) 2020-04-17 2021-10-21 Onk Therapeutics Limited High potency natural killer cells

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5879672A (en) * 1994-10-07 1999-03-09 Regeneron Pharmaceuticals, Inc. Tie-2 ligand 1
AU747602B2 (en) * 1997-06-04 2002-05-16 Oxford Biomedica (Uk) Limited Vector
JP2004526666A (ja) * 2000-09-11 2004-09-02 マスク ファウンデーション フォー リサーチ デヴェロップメント アポトーシスの選択的誘導によって腫瘍を治療するための組成物及び方法
AU2001297677B2 (en) * 2000-10-24 2007-07-05 Immunex Corporation Method for dendritic cells based immunotherapy of tumors using combination therapy
US7235358B2 (en) * 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
JP4493882B2 (ja) * 2001-06-19 2010-06-30 株式会社カネカ 抗原およびこの抗原を識別するモノクローナル抗体

Also Published As

Publication number Publication date
EP1771468A1 (en) 2007-04-11
BRPI0513855A (pt) 2008-05-20
ZA200701231B (en) 2008-08-27
RS51381B (sr) 2011-02-28
AU2005266543B2 (en) 2012-02-02
MX2007001152A (es) 2007-04-18
DE602005019050D1 (de) 2010-03-11
ES2340400T3 (es) 2010-06-02
IL180233A0 (en) 2007-07-04
JP5042826B2 (ja) 2012-10-03
RU2390558C2 (ru) 2010-05-27
US20070264231A1 (en) 2007-11-15
KR20070047757A (ko) 2007-05-07
DK1771468T3 (da) 2010-05-25
EP1771468B1 (en) 2010-01-20
SI1771468T1 (sl) 2010-07-30
CN101076540B (zh) 2012-10-24
WO2006010558A1 (en) 2006-02-02
IL180233A (en) 2010-12-30
WO2006010558A8 (en) 2006-08-24
AU2005266543A1 (en) 2006-02-02
RU2007107369A (ru) 2008-09-10
JP2008507961A (ja) 2008-03-21
NO20070956L (no) 2007-02-20
NZ552223A (en) 2009-01-31
CA2571426A1 (en) 2006-02-02
PL1771468T3 (pl) 2010-07-30
HRP20100227T1 (hr) 2010-07-31
CN101076540A (zh) 2007-11-21
ATE455847T1 (de) 2010-02-15
EP1621550A1 (en) 2006-02-01
HK1110874A1 (en) 2008-07-25

Similar Documents

Publication Publication Date Title
PT1771468E (pt) Células alojadas em tumores tratadas por engenharia genética para produzir ligandos que induzem apoptose relacionada com a necrose do tumor (liart)
ATE526987T1 (de) Dr5-antikörper und deren verwendung
MX2019009566A (es) Proteinas de union a bcma, nkg2d y cd16.
UY28926A1 (es) Adenovirus quiméricos para uso en el tratamiento del cáncer
IL188101A0 (en) Use of hif 1-alpha modulators for treatment of cancer
NO20091661L (no) Anvendelse av pegylert IL-10 for a behandle kreft
IL188594A0 (en) Anti-ccr7 receptor antibodies for the treatment of cancer
MX2009010269A (es) Metodos de tratamiento del cancer mediante administracion de combinaciones de interleucina-18 humana.
EA200800869A1 (ru) Модуляция экспрессии рецептора глюкагона
PE20081841A1 (es) Composiciones farmaceuticas con capacidad de induccion de apotosis en celulas tumorales, utiles para el diagnostico y tratamiento de la leucemia linfocitica cronica b
MX2024000678A (es) Agentes que codifican elementos de union a cldn6 y cd3 para el tratamiento de canceres positivos para cldn6.
MX2010005324A (es) Composiciones y metodos para inhibir el avance del tumor.
WO2007090125A3 (en) Prognostic factors for anti-hyperproliferative disease gene therapy
MXPA05007940A (es) Composiciones y metodos para el tratamiento del cancer usando igsf9 y liv-1.
DE602005007220D1 (de) Tetrahydropyridothiophenen zur verwendung in der behandlung von krebs
SG148035A1 (en) Gene products differentially expressed in cancerous breast cells and their methods of use
DE60231068D1 (de) Die Verwendung von 4-Pyridylmethylphthalazinen zur Behandlung von Nierentumoren
ATE435647T1 (de) Rutheniumkomplexe zur krebsbehandlung
MX2022006278A (es) Proteinas de salmon uk 114 para uso en el tratamiento, diagnostico y prevencion de tumores malignos.
Huo In Reply: Radiofrequency Ablation (RFA) of Pulmonary Metastases: Technical Success vs. Actual Benefit
MX2025008839A (es) Anticuerpos
GB0522298D0 (en) Agents that bind IgE
DK1730196T3 (da) EphB4-bindende antistoffer til inhibering af antiogenese og tumorvækst
DE602005023138D1 (de) Anti-cea scfv-beta-lactamase konstrukte (cab moleküle) in adept
Rossi Response of Anaplastic Thyroid Tumors to VEGF-Trap, an Anti-Angiogenic Agent